165 related articles for article (PubMed ID: 35046938)
1. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
2. USPs in Pancreatic Ductal Adenocarcinoma: A Comprehensive Bioinformatic Analysis of Expression, Prognostic Significance, and Immune Infiltration.
Wang Y; Zhou D; Kong Y; Yang Q; Ding Y; Wang W
Biomed Res Int; 2022; 2022():6109052. PubMed ID: 36582601
[TBL] [Abstract][Full Text] [Related]
3. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics.
Kou YQ; Yang YP; Pan ZJ; Du SS; Yuan WN; He K; Nie B
Med Sci Monit; 2023 Mar; 29():e938785. PubMed ID: 36905103
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
Jing Y; Wang F; Zhang K; Chen Z
BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma.
Liu WS; Feng YX; Li SN; Shao YJ; Wang K
Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559
[TBL] [Abstract][Full Text] [Related]
8. A novel refined pyroptosis and inflammasome-related genes signature for predicting prognosis and immune microenvironment in pancreatic ductal adenocarcinoma.
Zuo J; Yi C; Chen Z; Zhou B; Yang T; Lin J
Sci Rep; 2022 Nov; 12(1):18384. PubMed ID: 36319832
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G
J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel therapeutic target and prognostic biomarker in matrix metalloproteinase gene family in pancreatic cancer.
Luan H; Jian L; Huang Y; Guo Y; Zhou L
Sci Rep; 2023 Oct; 13(1):17211. PubMed ID: 37821678
[TBL] [Abstract][Full Text] [Related]
11. Tissue-resident CXCR4
Liao Z; Ye L; Li T; Jin X; Lin X; Fei Q; Zhang H; Shi S; Yu X; Jin K; Wu W
Int J Cancer; 2023 Jun; 152(11):2396-2409. PubMed ID: 36757203
[TBL] [Abstract][Full Text] [Related]
12. Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors.
Vance K; Alitinok A; Winfree S; Jensen-Smith H; Swanson BJ; Grandgenett PM; Klute KA; Crichton DJ; Hollingsworth MA
Cancer Biomark; 2022; 33(2):219-235. PubMed ID: 35213363
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract][Full Text] [Related]
14. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing.
Chen K; Wang Q; Liu X; Tian X; Dong A; Yang Y
J Transl Med; 2023 Mar; 21(1):210. PubMed ID: 36944944
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers.
Mi H; Sivagnanam S; Betts CB; Liudahl SM; Jaffee EM; Coussens LM; Popel AS
Cancer Res; 2022 Dec; 82(23):4359-4372. PubMed ID: 36112643
[TBL] [Abstract][Full Text] [Related]
16. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J; Wu Y; Cheng S; Yang W; Zhong L; Li Q; Fang L
Dig Dis Sci; 2023 May; 68(5):1913-1922. PubMed ID: 36515852
[TBL] [Abstract][Full Text] [Related]
17. Neuromedin U regulates the anti-tumor activity of CD8
Zheng R; Wang S; Wang J; Zhou M; Shi Q; Liu B
Cancer Sci; 2024 Feb; 115(2):334-346. PubMed ID: 38071753
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review.
Constantin AL; Cazacu IM; Stroescu C; Copăescu C; Săftoiu A
Rom J Morphol Embryol; 2021; 62(3):671-678. PubMed ID: 35263394
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Yu S; Lu Z; Chen J
Front Immunol; 2022; 13():1027459. PubMed ID: 36325339
[TBL] [Abstract][Full Text] [Related]
20. Exploiting inflammation for therapeutic gain in pancreatic cancer.
Steele CW; Jamieson NB; Evans TR; McKay CJ; Sansom OJ; Morton JP; Carter CR
Br J Cancer; 2013 Mar; 108(5):997-1003. PubMed ID: 23385734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
